Sai Life Sciences (NSE:SAILIFE) Ending Cash Position: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAILIFE Sai Life Sciences Ltd NSE:SAILIFE
19 GF Score
Price ₹1,461.00
! 4 Warning Signs
View Full Analysis

What is Sai Life Sciences Ending Cash Position?

Sai Life Sciences NSE:SAILIFE +0.38% 19 Ending Cash Position is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:SAILIFE with a GF Score™ of 19/100. The stock has 4 warning signs investors should review.

Sai Life Sciences's Ending Cash Position for the quarter that ended in Jun. 2026 was ₹0 Mil.

Sai Life Sciences's annual Ending Cash Position increased from Mar. 2024 (₹120 Mil) to Mar. 2025 (₹911 Mil) but then declined from Mar. 2025 (₹911 Mil) to Mar. 2026 (₹819 Mil).

Sai Life Sciences Ending Cash Position Related Terms

Sai Life Sciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Sai Life Sciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Life Sciences Ending Cash Position Chart

Sai Life Sciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
1,157.75 355.29 119.69 910.52 819.14

Sai Life Sciences Quarterly Data
Mar22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SAILIFE
19GF Score
Sai Life Sciences Ltd NSE:SAILIFE
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Life Sciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sai Life Sciences's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=910.52+-91.38
=819

Sai Life Sciences's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+0
=0

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ₹0 Mil mean?
Sai Life Sciences (NSE:SAILIFE) has a Ending Cash Position of ₹0 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sai Life Sciences and its competitors.
Is Sai Life Sciences' Ending Cash Position too high?
Sai Life Sciences' current Ending Cash Position is ₹0 Mil. Overall, Sai Life Sciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' Ending Cash Position compare to TMO and DHR?
Sai Life Sciences' Ending Cash Position of ₹0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Diagnostics & Research company?
A good Ending Cash Position depends on the Medical Diagnostics & Research industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sai Life Sciences and its competitors. Sai Life Sciences's current Ending Cash Position is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current Ending Cash Position of ₹0 Mil. The current Ending Cash Position is ₹0 Mil. Sai Life Sciences' overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current Ending Cash Position is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Life Sciences Business Description

Other Exchanges 544306:India
Address Gachibowli Miyapur Road, L4- 01 & 02, SLN Terminus Survey, Survey no. 133, Gachibowli, Hyderabad, TG, IND, 500032
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
19GF Score

Get the complete analysis for NSE:SAILIFE

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,461.00
Price